University of Washington

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Washington sits in the top decile of US sponsors by registered trial count (#30 of 15,742 sponsors by registered trial count).

1,048 total trials 156 currently recruiting 720 completed early-phase tilt top decile by trial count

University of Washington: 1,048 sponsored US clinical trials, 156 recruiting.

University of Washington sponsors 1,048 registered US clinical trials on ClinicalTrials.gov, 156 of them currently recruiting, and 720 completed. 104 of these trials are in Phase 3-4 (later-stage) and 320 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 13 trials.

Top-decile sponsor footprint

University of Washington ranks in the top decile of sponsors by registered trial count (#30 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 60/100

720 of 816 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,048 total, page 5 of 21

ACTIVE NOT RECRUITING NA

Guiding Good Choices for Health

NCT04040153

ACTIVE NOT RECRUITING NA

Intraoperative Assessment of of Burst Wave Lithotripsy (BWL)

NCT03873259

ACTIVE NOT RECRUITING

CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer

NCT03933826

ACTIVE NOT RECRUITING

Non-contrast DWI for Supplemental Screening

NCT03607552

ACTIVE NOT RECRUITING

MRI Characterization of Mammographically Detected DCIS

NCT03495011

ACTIVE NOT RECRUITING Phase 3

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

NCT03040778

ACTIVE NOT RECRUITING NA

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

NCT03389347

ACTIVE NOT RECRUITING Phase 3

Adjuvant Avelumab in Merkel Cell Cancer

NCT03271372

ACTIVE NOT RECRUITING Phase 2

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

NCT02339922

ACTIVE NOT RECRUITING Phase 1

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

NCT02157051

ACTIVE NOT RECRUITING NA

Ultrasound Imaging of Kidney Stones and Lithotripsy

NCT02214836

ACTIVE NOT RECRUITING NA

Safety and Effectiveness of the Ultrasonic Propulsion of Kidney Stones

NCT02028559

ACTIVE NOT RECRUITING

Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy

NCT03738553

ACTIVE NOT RECRUITING Phase 2

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

NCT01703949

ACTIVE NOT RECRUITING

Genomics of Sudden Cardiac Arrest

NCT00661128

ACTIVE NOT RECRUITING NA

The Community Youth Development Study: A Test of Communities That Care

NCT01088542

NOT YET RECRUITING NA

VOCALE LBD: Online Peer Support for Caregivers of People With Lewy Body Dementia

NCT07637097

NOT YET RECRUITING Phase 2

[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma

NCT07673341

NOT YET RECRUITING Phase 2

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

NCT07322341

NOT YET RECRUITING NA

Inherited and Environmental Risks Acting on Body Weight

NCT07430852

NOT YET RECRUITING NA

My MS Toolkit: An Internet-Based Depression Self-Management Program for Adults Living With Multiple Sclerosis

NCT07636434

NOT YET RECRUITING Phase 2

Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial

NCT07332351

NOT YET RECRUITING Phase 2

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

NCT07466498

NOT YET RECRUITING NA

A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant

NCT07616921

NOT YET RECRUITING Phase 1

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

NCT07579195

NOT YET RECRUITING Phase 2

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

NCT07495124

NOT YET RECRUITING Phase 1

Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

NCT07645651

NOT YET RECRUITING Phase 4

Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty

NCT07598734

NOT YET RECRUITING NA

Dry Weight Reduction Intervention Via Extra Ultrafiltration

NCT07637110

NOT YET RECRUITING NA

Improving Health Among Disadvantaged Girls to Slow Pubertal Onset and Reduce Long-term Health Risks

NCT07460544

NOT YET RECRUITING NA

CPNF Intervention Development and Testing

NCT07036198

NOT YET RECRUITING NA

Skills for Talking About Cannabis for Families of Young Adults With Psychosis

NCT06961877

COMPLETED NA

Decisions During Drinking

NCT06978140

COMPLETED NA

Magic Bowl Virtual Reality Analgesia

NCT07192822

COMPLETED NA

Up, Down, and All Around: Evaluating Mobility Devices for Young Children With Developmental Disabilities and Delays

NCT06591559

COMPLETED NA

One-step HCV RNA Testing Among SSP Participants (HOT Study)

NCT06634342

COMPLETED Phase 1

Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial

NCT06661902

COMPLETED NA

The Effect of Virtual Reality on Pain and Memory.

NCT06871423

COMPLETED NA

Ambient AI Clinical Trial

NCT07598721

TERMINATED Phase 1

ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT06588660

COMPLETED Phase 1

A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer

NCT06644170

COMPLETED NA

DMHI for At-Risk College Students

NCT06608498

COMPLETED Phase 4

Prevention and Treatment of Common Hyperglycemia in Surgery Pilot

NCT06624956

TERMINATED NA

Testing Educational Videos on Conservative Kidney Management

NCT06577571

COMPLETED NA

Real-world Experiences of Alcohol and Cognitions Over Time

NCT06579521

COMPLETED NA

Cognitive Conditioned Pain Modulation

NCT07234123

COMPLETED NA

Decreasing Loneliness to Optimize Pain Care

NCT06285032

COMPLETED NA

Pain Relief With Integrative Medicine (PRIMe)?: Feasibility of Acupuncture for Long COVID

NCT06476496

COMPLETED NA

Parenting Support for Justice Involved Families

NCT06329336

COMPLETED NA

The Effective of Immersive Virtual Reality Distraction on Memory: Study 1

NCT07172230

← Previous Page 5 of 21 Next →

What is open in the University of Washington pipeline

156 recruiting of 1,048 indexed (15% open); 720 completed (69%).

Phase mix: 104 late (III/IV) vs 320 early (I/II) (early-phase heavy).

Top condition: Depression (13 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Washington: open-pipeline peers nationwide

Peers matched on 1,048 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

University of Washington sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 6%8%10%12%14%16% Total trials Recruiting share University of WashingtonUniversity of Wisconsin, MadisonBristol-Myers SquibbUniversity of FloridaUniversity of North Carolina, Chapel HillDompé Farmaceutici S.p.AVanderbilt-Ingram Cancer CenterArizona State UniversityGeorgetown University
University of Washington sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Washington sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,048 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this University of Washington page

1,048 registered trials is a research-attention snapshot, not an endorsement of University of Washington or any single study.

  • 156 of University of Washington's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition University of Washington studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Washington pipeline card: 1,048 registered trials from official public datasets.Report a data error.